About us

Chronology /History

Milestones

  • 2015
  • December 2015

    Foundation

  • 2016
  • June 2016

    NEOTEC - CDTi

  • July 2016

    Seed capital from
    Funcación Marcelino Botín

  • 2017
  • 2018
  • 2019
  • December 2019

    Senén Vilaró award to
    the Best innovative startup

  • 2020
  • December 2020

    Breakeven point

  • 2021
  • 2016
  • September 2016

    1st internal DD project

  • October 2016

    First DD contract

  • 2017
  • 2018
  • December 2018

    BioExcel project granted - H2020-EC

  • 2019
  • June 2019

    First PCT granted for an NCE in cardiovascular therapeutic area

  • 2020
  • 2021
  • 2019
  • May 2019

    Enzyme Engineering Division created

  • June 2019

    EE first contract in Europe

  • August 2019

    EE first contract in the USA

  • 2020
  • January 2020

    First PluriZyme in the PDB

  • November 2020

    Protein Engineering Congress EU Sponsor

  • 2021
  • 2020
  • May 2020

    Nucleic Acids division created

  • June 2020

    First client

  • 2021
  • 2016
  • May 2016

    ED/MD is transferred

  • September 2016

    PELE is transferred

  • 2017
  • February 2017

    PELEplat 1.0 launch

  • 2018
  • August 2018

    PELE++ success case
    Paper with ESTEVE

  • 2019
  • October 2019

    pyDock considered one of the best PPI software in CASP13-CAPRI experiment

  • November 2019

    PELE++ success case
    Paper with Almirall

  • December 2019

    PELE++ success case
    Paper with Janssen Pharmaceutica

  • 2020
  • July 2020

    pyDock is transferred

  • September 2020

    PELE++ success case
    Paper with Emerald

  • PELEplat DD/EE/AI

  • 2021

NBD | Nostrum Biodiscovery is a joint spin-off of the Barcelona Supercomputing Center (BSC-CNS), the Institute for Research in Biomedicine of Barcelona (IRB Barcelona), the Catalan Institution for Research and Advanced Studies (ICREA) and the University of Barcelona (UB), that was created to commercially exploit a series of computational tools developed by Professors Víctor Guallar and Modesto Orozco.

NBD uses its own proprietary modeling technologies with structure and ligand-based simulations, artificial intelligence algorithms, and supercomputing capacity to speed up, increasing the success ratio, and profitability of the drug design and the directed enzyme evolution processes.

Moreover, the proprietary technologies are grouped in a very adaptable and customizable software platform that can be licensed to any company either developing new small molecules, enhancing enzymes or facing molecular modeling challenges in their day to day activity.

Finally, NBD has a portfolio of co-developed products with some of our clients.

 

Purpose and Vision

Purpose

To deliver the modeling technology and expertise for your molecular design needs.

Vision

In silico modeling will drive future biotechnology projects.

KNOW OUR TESTIMONIALS

DISCOVER OUR TESTIMONIALS

KNOW OUR TEAM

DISCOVER OUR TEAM